Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Erasca, Inc.ERAS · Entity 3796 | Director | June 26, 2026 | June 29, 2026 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Chief Medical Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Erasca, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 · Expires 2036-06-26 | Direct | 29,888 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 29,888 · Balance 29,888 F1: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date.
Oric Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01 | Direct | 214,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 214,000 · Balance 214,000 F1: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 35,500 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 35,500 · Balance 35,500 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
F3: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHIMERIX INC
Report date April 21, 2025 · Filed April 21, 2025
Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2030-02-20 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.85 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-21 · Disposition to issuer · Disposed 35,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2031-06-22 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-21 · Disposition to issuer · Disposed 35,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-21 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2034-06-19 | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]
F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.
F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).
Ignyta, Inc.
Report date February 08, 2018 · Filed February 12, 2018
Section 16 reporting ended · disclosed 2018-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 1
1 source rowRow 1 · 2018-02-08 · Disposition to issuer · Disposed 74,134 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2025-02-16 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-08 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2027-01-04 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-08 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").
F2: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 29, 2026 23:05 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 29,888 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001193125-26-288906 · ownership.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,888 Underlying: Common Stock · 29,888 shares Expires 2036-06-26 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:41 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-26-000002 · form4-01062026_090111.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:41 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 214,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001586894-26-000002 · form4-01062026_090111.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,000 Underlying: Common Stock · 214,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 14:00 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 19,532 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001193125-26-001609 · ownership.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,532 Underlying: Common Stock · 19,532 shares Expires 2036-01-01 F1 · security: At the election of the filing person the option grant was issued in lieu of the cash compensation payable to such person in 2026 in connection with each position on the issuer's board of directors and its committees for which such person is anticipated to serve in 2026. F2 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12 increments beginning one month from the date of grant, subject to such person continuing to serve on the issuer's board of directors through the applicable vesting date. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 10,720 | $9.06 | $97,128.56 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · nonDerivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,149 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · derivative · entry 5 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 11,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · derivative · entry 4 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 29,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001586894-25-000005 · form4-12182025_121256.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:25 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 120,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000950170-25-090420 · ownership.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 24, 2026, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| May 23, 2025 Filed Jun 3, 2025 20:15 UTC | Erasca, Inc. ERAS · Entity 3796 | GiftCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080941 · ownership.xml · nonDerivative · entry 2 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Multani Family Trust U/A DTD 08/10/2006 Disclosed balance after: 6,200 F1 · acquired: The Reporting Person transferred 6,200 shares of common stock to a family trust for no consideration, for estate planning purposes. The Reporting Person holds all voting and dispositive power with respect to the securities held by the trust and remains the beneficial owner of such securities. Read SEC document |
| May 23, 2025 Filed Jun 3, 2025 20:15 UTC | Erasca, Inc. ERAS · Entity 3796 | GiftCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080941 · ownership.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,666 F1 · acquired: The Reporting Person transferred 6,200 shares of common stock to a family trust for no consideration, for estate planning purposes. The Reporting Person holds all voting and dispositive power with respect to the securities held by the trust and remains the beneficial owner of such securities. Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 16:15 UTC | CHIMERIX INC CMRX · Entity 80651 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $0.89 | Not disclosed |
DisclosureSEC source: 0001415889-25-011078 · form4-04212025_080407.xml · derivative · entry 6 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2034-06-19 F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 16:15 UTC | CHIMERIX INC CMRX · Entity 80651 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001415889-25-011078 · form4-04212025_080407.xml · derivative · entry 5 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2033-06-08 F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 16:15 UTC | CHIMERIX INC CMRX · Entity 80651 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $1.82 | Not disclosed |
DisclosureSEC source: 0001415889-25-011078 · form4-04212025_080407.xml · derivative · entry 4 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2032-06-22 F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 16:15 UTC | CHIMERIX INC CMRX · Entity 80651 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 35,000 | Not disclosed Strike: $7.84 | Not disclosed |
DisclosureSEC source: 0001415889-25-011078 · form4-04212025_080407.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2031-06-22 F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 16:15 UTC | CHIMERIX INC CMRX · Entity 80651 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 35,000 | Not disclosed Strike: $2.85 | Not disclosed |
DisclosureSEC source: 0001415889-25-011078 · form4-04212025_080407.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2030-06-10 F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 16:15 UTC | CHIMERIX INC CMRX · Entity 80651 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $1.73 | Not disclosed |
DisclosureSEC source: 0001415889-25-011078 · form4-04212025_080407.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2030-02-20 F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000602 · form4-01032025_100144.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 202,500 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001415889-25-000602 · form4-01032025_100144.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,500 Underlying: Common Stock · 202,500 shares Expires 2035-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2026, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:22 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 8,850 | $8.28 | $73,293.05 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · nonDerivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,765 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 8,850 shares sold in the price range of $8.27 to $8.41 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:22 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · derivative · entry 5 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:22 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · derivative · entry 4 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:22 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 6,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:22 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 24,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 11:16 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001415889-24-017773 · form4-06212024_030641.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 12:39 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-24-005919 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 20, 2025, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:20 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000368 · doc4.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:20 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-24-000368 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 14:00 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 32,867 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001209191-24-000271 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,867 Underlying: Common Stock · 32,867 shares Expires 2034-01-01 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments beginning one month from the date of grant, subject to such person's continuing in service on the board through the applicable vesting date. F2 · derivative.underlying_shares: At the election of the filing person, the option grant was issued in lieu of direct cash compensation payable to such person in 2024 in connection with each position on the board and its committees for which such person is anticipated to serve in 2024. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059266 · doc4.xml · derivative · entry 4 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 6,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059266 · doc4.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,042 Underlying: Common Stock · 6,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 5,282 | $8.59 | $45,350.72 |
DisclosureSEC source: 0001209191-23-059266 · doc4.xml · nonDerivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,809 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 5,282 shares sold in the price range of $8.57 to $8.795 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 14,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059266 · doc4.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 13:14 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-039588 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2024, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 16:31 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001209191-23-036334 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:13 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006198 · doc4.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:13 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006198 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:51 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061756 · doc4.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,084 Underlying: Common Stock · 6,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F4 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F4 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:51 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,089 | $3.25 | $6,789.25 |
DisclosureSEC source: 0001209191-22-061756 · doc4.xml · nonDerivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,423 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:51 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061756 · doc4.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 3,471 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| December 15, 2022 Filed Feb 17, 2023 21:25 UTC Amendment | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,227 | $3.07 | $6,845.58 |
DisclosureSEC source: 0001209191-23-010616 · doc4a.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,285 F1 · kind: This amendment is filed to correct the number of shares sold, and the price per share at which the shares were sold, to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. F1 · shares: This amendment is filed to correct the number of shares sold, and the price per share at which the shares were sold, to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. F1 · price: This amendment is filed to correct the number of shares sold, and the price per share at which the shares were sold, to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:08 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 108,750 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042843 · doc4.xml · derivative · entry 6 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,750 Underlying: Common Stock · 108,750 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F6 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:08 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042843 · doc4.xml · derivative · entry 5 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F6 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:08 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 147,500 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042843 · doc4.xml · derivative · entry 4 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,500 Underlying: Common Stock · 147,500 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F5 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:08 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 108,750 | Not disclosed Strike: $9.48 | Not disclosed |
DisclosureSEC source: 0001209191-22-042843 · doc4.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,750 shares Expires 2032-01-31 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F4 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option would have vested on February 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option would have vested each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:08 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $29.83 | Not disclosed |
DisclosureSEC source: 0001209191-22-042843 · doc4.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2031-01-31 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F3 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option vested on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:08 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 147,500 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-042843 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 147,500 shares Expires 2030-04-22 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F1 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option vested on April 23, 2021, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 11:13 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001209191-22-039120 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2023 annual stockholder meeting. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 13:18 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-22-039105 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.